TABLE 2.
Comparison of recurrence rates in relation to genomic changes in HBV and clinical characteristics
| Variable | Univariate analysis P |
Multivariate analysis P |
HR (95 % CI) |
|---|---|---|---|
| Characteristic | |||
| Genomic changes | |||
| BCP, wild type/mutant | 0.139 | – | – |
| Precore, wild type/mutant | 0.944 | – | – |
| X C1653T, wild type/mutant | 0.368 | – | – |
| X T1753V, wild type/mutant | 0.558 | – | – |
| Pre-S2, wild type/deletion | 0.657 | – | – |
| Clinical characteristics | |||
| Age ≤40 y | 0.031 | 0.601 | 0.601 (0.214–1.687) |
| Male | 0.002 | 0.595 | 0.595 (0.223–1.587) |
| Serum HBV DNA > 105 copies/ml | 0.089 | 0.984 | 1.007 (0.502–2.019) |
| Serum AFP > 200 ng/mL | 0.001 | 0.354 | 1.462 (0.655–3.261) |
| Serum ALT > 80 IU/L | 0.136 | 0.461 | 1.511 (0.504–4.530) |
| Advanced MELD score | 0.041 | 0.075 | 4.076 (0.869–19.110) |
| Tumor characteristics | |||
| Size >5 cm | <0.001 | 0.135 | 1.768 (0.838–3.731) |
| Differentiation, E-S grade 3–4 | 0.035 | 0.532 | 0.798 (0.392–1.622) |
| Microvascular invasion | <0.001 | <0.001 | 5.406 (2.437–11.991) |
| Advanced CLIP stage | 0.107 | 0.930 | 1.036 (0.470–2.284) |
HBV hepatitis B virus, HR hazard ratio, CI confidence interval, BCP basal core promoter, AFP α-fetoprotein, ALT alanine aminotransferase, MELD Model for End-Stage Liver Disease, E-S grade Edmondson–Steiner grade, CLIP Cancer of the Liver Italian Program